SEARCH

SEARCH BY CITATION

References

  • 1
    Yatham LN, Kennedy SH, O’Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7 (Suppl. 3): 569.
  • 2
    Yatham LN, Kennedy SH, O’Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006; 8: 721739.
  • 3
    Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543552.
  • 4
    Ghaemi SN, Bauer M, Cassidy F et al. Diagnostic guidelines for bipolar disorder: a summary of the International Society for Bipolar Disorders Diagnostic Guidelines Task Force Report. Bipolar Disord 2008; 10: 117128.
  • 5
    Takeshima M, Kitamura T, Kitamura M et al. Impact of depressive mixed state in an emergency psychiatry setting: a marker of bipolar disorder and a possible risk factor for emergency hospitalization. J Affect Disord 2008; 111: 5260.
  • 6
    O’Donovan C, Garnham JS, Hajek T, Alda M. Antidepressant monotherapy in pre-bipolar depression; predictive value and inherent risk. J Affect Disord 2008; 107: 293298.
  • 7
    Lopez J, Baca E, Botillo C et al. Diagnostic errors and temporal stability in bipolar disorder. Actas Esp Psiquiatr 2008; 36: 205209.
  • 8
    Benazzi F. Challenging the unipolar-bipolar division: does mixed depression bridge the gap? Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 97103.
  • 9
    Agosti V, Stewart JW. Hypomania with and without dysphoria: comparison of comorbidity and clinical characteristics of respondents from a national community sample. J Affect Disord 2008; 108: 177182.
  • 10
    Morriss R. Implementing clinical guidelines for bipolar disorder. Psychol Psychother 2008; 81: 437458.
  • 11
    Zimbroff DL, Marcus RN, Manos G et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007; 27: 171176.
  • 12
    Centorrino F, Meyers AL, Ahl J et al. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder. Hum Psychopharmacol 2007; 22: 455462.
  • 13
    Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007; 9: 551560.
  • 14
    Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64: 442455.
  • 15
    Niufan G, Tohen M, Qiuqing A et al. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J Affect Disord 2008; 105: 101108.
  • 16
    Rendell JM, Gijsman HJ, Bauer MS, Goodwin GM, Geddes GR. Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev 2006; CD004043.
  • 17
    Perlis RH, Baker RW, Zarate CA Jr et al. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry 2006; 67: 17471753.
  • 18
    Bowden CL, Grunze H, Mullen J et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66: 111121.
  • 19
    McIntyre R, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania—a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005; 15: 573585.
  • 20
    Delbello M, Schwiers M, Rosenberg H, Strakowski S. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41: 12161223.
  • 21
    Sachs G, Chengappa K, Suppes T et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004; 6: 213223.
  • 22
    Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004; 24: 599606.
  • 23
    Ketter TA, Jones M, Paulsson B. Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania. J Affect Disord 2007; 100 (Suppl. 1): S45S53.
  • 24
    Sussman N, Mullen J, Paulsson B, Vagero M. Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania. J Affect Disord 2007; 100 (Suppl. 1): S55S63.
  • 25
    Brahm NC, Gutierres SL, Carnahan RM. Quetiapine for acute mania in bipolar disorder. Am J Health Syst Pharm 2007; 64: 10451053.
  • 26
    Adler CM, Fleck DE, Brecher M, Strakowski SM. Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder. J Affect Disord 2007; 100 (Suppl. 1): S15S22.
  • 27
    Vieta E, Goldberg JF, Mullen J, Vagero M, Paulsson B. Quetiapine in the treatment of acute mania: target dose for efficacious treatment. J Affect Disord 2007; 100 (Suppl. 1): S23S31.
  • 28
    McIntyre RS, Konarski JZ, Jones M, Paulsson B. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms. J Affect Disord 2007; 100 (Suppl. 1): S5S14.
  • 29
    Cutler A, Datto C, Nordenhem A et al. Effectiveness of extended-release formulation of quetiapine as monotherapy for the treatment of acute bipolar mania (trial D144CC00004) [abstract NR3-006]. Annual meeting of the American Psychiatric Association. Washington, D.C., 2008.
  • 30
    Sachs G, Sanchez R, Marcus R et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20: 536546.
  • 31
    Keck P, Marcus R, Tourkodimitris S et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 16511658.
  • 32
    Vieta E, Bourin M, Sanchez R et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005; 187: 235242.
  • 33
    Suppes T, Eudicone J, McQuade R, Pikalov A III, Carlson B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord 2008; 107: 145154.
  • 34
    Sachs GS, Gaulin BD, Gutierrez-Esteinou R et al. Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. J Clin Psychiatry 2007; 68: 13771383.
  • 35
    Vieta E, T’joen C, McQuade RD et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008; 165: 13161325.
  • 36
    Vieta E, Pappadopulos E, Mandel F. Early partial response to ziprasidone predicts later treatment response in patients with bipolar disorder. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 2008.
  • 37
    Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007; 115: 1220.
  • 38
    Vieta E, Berwaerts J, Nuamah I et al. Randomized, placebo, active-controlled study of paliperidone extended-release (ER) for acute manic and mixed episodes in bipolar I disorder. J Eur Coll Neuropsychopharmacol 2008; 18 (Suppl. 4): S369.
  • 39
    Cutler A A randomized, double-blind, placebo-controlled, parallel-group, dose-response, multicenter study to evaluate the efficacy and safety of three fixed doses of extended-release paliperidone (3, 6, and 12 mg/day) in the treatment of subjects with acute manic and mixed episodes associated with bipolar I disorder. Veritas Medicine. January 7, 2008. Available at: http://www.download.veritasmedicine.com/PDF/CR010834_CSR.pdf. Accessed February 11, 2009.
  • 40
    Hirschfeld R, Panagides J, Alphs L et al. Asenapine in acute mania: a randomized, double-blind, placebo- and olanzapine-controlled trial (Ares 7501005) [Abstract NR333]. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 2007.
  • 41
    Panagides J, McIntyre R, Alphs L et al. Asenapine in acute mania: a randomized, double-blind, placebo- and olanzapine-controlled trial (ARES 7501004). Biol Psychiatry 2007; 61: 222S.
  • 42
    McIntyre R, Hirschfeld R, Alphs L, Cohen M, Macek T, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: outcomes from two randomized placebo-controlled trials. Bipolar Disord 2008; 10 (Suppl. 1): 49.
  • 43
    Calabrese J, Cohen M, Zhao J, Panagides J Efficacy and safety of asenapine as adjunctive treatment for acute mania associated with bipolar disorder [Abstract NR3-061]. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 2008.
  • 44
    Cipriani A, Rendell JM, Geddes JR. Haloperidol alone or in combination for acute mania. Cochrane Database Syst Rev 2006; 3: CD004362.
  • 45
    Yildiz A, Guleryuz S, Ankerst DP, Ongur D, Renshaw PF. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 2008; 65: 255263.
  • 46
    Zarate CA Jr, Singh JB, Carlson PJ et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 2007; 9: 561570.
  • 47
    Kulkarni J, Garland KA, Scaffidi A et al. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 2006; 31: 543547.
  • 48
    Kulkarni J, Mu L, De Castella A et al. Tamoxifen – a potential treatment for women in the manic phase of bipolar affective disorder?. Bipolar Disord 2008; 10 (Suppl. 1): 80.
  • 49
    Wagner KD, Kowatch RA, Emslie GJ et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006; 163: 11791186.
  • 50
    Applebaum J, Bersudsky Y, Klein E. Rapid tryptophan depletion as a treatment for acute mania: a double-blind, pilot-controlled study. Bipolar Disord 2007; 9: 884887.
  • 51
    Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 2006; 8: 485489.
  • 52
    Thomas P, Vieta E, for the SOLMANIA study group. Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial. Neuropsychiatr Dis Treat 2008; 4: 112.
  • 53
    Tohen M, Bowden CL, Smulevich AB et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008; 192: 135143.
  • 54
    Riesenberg R. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of flexibly-dosed extended-release paliperidone as adjunctive therapy to mood stabilizers in the treatment of acute manic and mixed episodes associated with bipolar I disorder. Veritas Medicine. Feb 25, 2008. Available at: http://www.download.veritasmedicine.com/PDF/CR010855_CSR.pdf. Accessed February 11, 2009.
  • 55
    Tamayo JM, Mazzotti G, Tohen M et al. Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol. J Clin Psychopharmacol 2007; 27: 126134.
  • 56
    Miklowitz DJ, Otto MW, Frank E et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 2007; 64: 419426.
  • 57
    Miklowitz DJ, Otto MW, Frank E et al. Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry 2007; 164: 13401347.
  • 58
    Calabrese J, Bowden C, Sachs G et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 7988.
  • 59
    Frye M, Ketter T, Kimbrell T et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607614.
  • 60
    Calabrese JR, Huffman RF, White RL et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008; 10: 323333.
  • 61
    Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194: 49.
  • 62
    Calabrese JR, Keck PE Jr, Macfadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 13511360.
  • 63
    Thase ME, Macfadden W, Weisler RH et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26: 600609.
  • 64
    Young A, Carlsson A, Olausson B, Paulsson B, Brecher M. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine and lithium in adults with bipolar depression (EMBOLDEN I) [Abstract NR 3-004]. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 2008.
  • 65
    Olausson B, Young A, Carlsson A et al. A double-blind, placebo-controlled study of quetiapine and paroxetine in adults with bipolar depression (EMBOLDEN II) [Abstract NR 3-013]. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 2008.
  • 66
    Suppes T, Datto C, Minkwitz M et al. Effectiveness of the new extended-release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression (trial D144CC00002) [abstract NR3-124]. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 2008.
  • 67
    Sachs GS, Nierenberg AA, Calabrese JR et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356: 17111722.
  • 68
    Goldberg JF, Perlis RH, Ghaemi SN et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry 2007; 164: 13481355.
  • 69
    Frye MA, Grunze H, Suppes T et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007; 164: 12421249.
  • 70
    Nasr S, Wendt B, Steiner K. Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice. J Affect Disord 2006; 95: 111114.
  • 71
    Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs 2008; 68: 18031839.
  • 72
    Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005; 85: 259266.
  • 73
    Ghaemi SN, Gilmer WS, Goldberg JF et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007; 68: 18401844.
  • 74
    Muzina D, Khalife S, Gao K et al. A double-blind, placebo-controlled study of divalproex ER in newly diagnosed mood stabilizer naïve patients with acute bipolar depression [Abstract NR3-028]. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 2008.
  • 75
    Nolen WA, Kupka RW, Hellemann G et al. Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand 2007; 115: 360365.
  • 76
    Berk M, Copolov DL, Dean O et al. N-acetyl cysteine for depressive symptoms in bipolar disorder – a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64: 468475.
  • 77
    Thase ME, Jonas A, Khan A et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008; 28: 1320.
  • 78
    Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry 2006; 18: 169172.
  • 79
    Sokolski KN. Adjunctive aripiprazole in bipolar I depression. Ann Pharmacother 2007; 41: 3540.
  • 80
    Dunn RT, Stan VA, Chriki LS, Filkowski MM, Ghaemi SN. A prospective, open-label study of aripiprazole mono- and adjunctive treatment in acute bipolar depression. J Affect Disord 2008; 110: 7074.
  • 81
    Kemp DE, Gilmer WS, Fleck J et al. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 574577.
  • 82
    Schule C, Baghai TC, Eser D et al. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. World J Biol Psychiatry 2007; 8: 112122.
  • 83
    McElroy SL, Suppes T, Frye MA et al. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. J Affect Disord 2007; 101: 275281.
  • 84
    Johnson FR, Ozdemir S, Manjunath R et al. Factors that affect adherence to bipolar disorder treatments: a stated-preference approach. Med Care 2007; 45: 545552.
  • 85
    Perlis RH, Ostacher MJ, Patel JK et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006; 163: 217224.
  • 86
    Schneck CD, Miklowitz DJ, Miyahara S et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry 2008; 165: 370377.
  • 87
    Judd LL, Schettler PJ, Akiskal HS et al. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry 2008; 65: 386394.
  • 88
    McElroy SL, Bowden CL, Collins MA et al. Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder. J Affect Disord 2008; 107: 127133.
  • 89
    Morriss RK, Faizal MA, Jones AP et al. Interventions for helping people recognise early signs of recurrence in bipolar disorder. Cochrane Database Syst Rev 2007; CD004854.
  • 90
    Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes J. Psychosocial interventions for the prevention of relapse in bipolar disorder: systematic review of controlled trials. Br J Psychiatry 2008; 192: 511.
  • 91
    Soares-Weiser K, Bravo Vergel Y, Beynon S et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 2007; 11: iiiiv, ix–206.
  • 92
    Justo LP, Soares BG, Calil HM. Family interventions for bipolar disorder. Cochrane Database Syst Rev 2007; CD005167.
  • 93
    Reinares M, Colom F, Sanchez-Moreno J et al. Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: a randomized controlled trial. Bipolar Disord 2008; 10: 511519.
  • 94
    Ball JR, Mitchell PB, Corry JC et al. A randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change. J Clin Psychiatry 2006; 67: 277286.
  • 95
    Williams JM, Alatiq Y, Crane C et al. Mindfulness-based Cognitive Therapy (MBCT) in bipolar disorder: preliminary evaluation of immediate effects on between-episode functioning. J Affect Disord 2008; 107: 275279.
  • 96
    Parikh S, Zaretsky A, Beaulieu S et al. Psycho-education versus cognitive behavioural therapy for bipolar disorder: A multi-site national RCT [Abstract NR322]. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 2007.
  • 97
    Zaretsky A, Lancee W, Miller C, Harris A, Parikh SV. Is cognitive-behavioural therapy more effective than psychoeducation in bipolar disorder? Can J Psychiatry 2008; 53: 441448.
  • 98
    Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007; 9: 394412.
  • 99
    Young A, McElroy S, Olausson B et al. Quetiapine Monotherapy up to 52 weeks in patients with bipolar depression: continuation phase data from EMBOLDEN I & II [Abstract]. Barcelona, Spain: 21st ENCP Conference, 2008.
  • 100
    Nolen W. New Clinical Data in the Maintenance Treatment of Bipolar Disorder. Presented at an AstraZeneca satellite symposium, “New advances for patients with bipolar disorder: a focus on the latest clinical trial data.”. Barcelona, Spain: 21st ECNP Conference, 2008.
  • 101
    Vieta E, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium/divalproex as maintenance treatment for bipolar I disorder. Bipolar Disord 2008; 10 (Suppl. 1): 57.
  • 102
    Suppes T, Liu S, Brecher M, Paulsson B, Lazarus A. Maintenance treatment in bipolar I disorder with quetiapine concomitant with lithium or divalproex: a placebo-controlled, randomized multicenter trial (Trial D1447C00127). Bipolar Disord 2008; 10 (Suppl. 1): 40.
  • 103
    Brecher M, Anderssen H, Paulsson P. Quetiapine in the maintenance treatment of bipolar I disorder: combined data from Two long-term, phase III studies [NR 3–007]. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 2008.
  • 104
    Biel MG, Peselow E, Mulcare L, Case BG, Fieve R. Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study. Bipolar Disord 2007; 9: 435442.
  • 105
    Rosa AR, Marco M, Fachel JM et al. Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 217224.
  • 106
    Davis LL, Li X, Bartolucci AA, Williford RB, Lowe JS. A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex. J Clin Psychiatry 2007; 68: 15461551.
  • 107
    Yatham LN. Current Maintenance Treatments for Bipolar Disorder. Presented at a Janssen-Ortho, Inc., Satellite symposium, “Long term management of bipolar disorder.” XVII CINP. Munich, 2008.
  • 108
    Alphs L, Haskins J, Turkoz I et al. Adjunctive long-acting risperidone delays mood episode relapse in patients with frequently relapsing bipolar disorder [Abstract P.3.c.066]. J Eur Coll Neuropsychopharmacol 2008; 18 (Suppl. 4): S441.
  • 109
    Keck PE Jr, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626637.
  • 110
    Keck PE Jr, Calabrese JR, McIntyre RS et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68: 14801491.
  • 111
    Forbes A, Findling R, Nyilas M et al. Long-term efficacy of aripiprazole in pediatric patients with bipolar I disorder [Abstract NR6-049]. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 2008.
  • 112
    Vieta E, Bowden C, Ice K et al. A six-month, randomized, placebo-controlled, double blind trial of ziprasidone plus a mood stabilizer in subjects with bipolar I disorder [Abstract]. 17th European Congress of Psychiatry. Lisbon, Portugal: European Psychiatric Association, 2009.
  • 113
    Vieta E, Cruz N, Garcia-Campayo J et al. A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol 2008; 11: 445452.
  • 114
    Payne JL, Roy PS, Murphy-Eberenz K et al. Reproductive cycle-associated mood symptoms in women with major depression and bipolar disorder. J Affect Disord 2007; 99: 221229.
  • 115
    Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356: 26842692.
  • 116
    Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356: 26752683.
  • 117
    Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160: 173176.
  • 118
    Chambers CD, Hernandez-Diaz S, Van Marter LJ et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579587.
  • 119
    Newham JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Williams RH. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry 2008; 192: 333337.
  • 120
    Newport DJ, Calamaras MR, DeVane CL et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 2007; 164: 12141220.
  • 121
    Viguera AC, Whitfield T, Baldessarini RJ et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007; 164: 18171824.
  • 122
    Newport DJ, Stowe ZN, Viguera AC et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord 2008; 10: 432436.
  • 123
    Cunnington MC. The international lamotrigine pregnancy registry update for the epilepsy foundation. Epilepsia 2004; 45: 1468.
  • 124
    Food and Drug Administration. Information for Healthcare Professionals. Lamotrigine (marketed as Lamictal). Jan 31, 2008. Available at: http://www.fda.gov/CDER/drug/InfoSheets/HCP/lamotrigineHCP.htm. Accessed January 24, 2009.
  • 125
    Munk-Olsen T, Laursen TM, Pedersen CB, Mors O, Mortensen PB. Family and partner psychopathology and the risk of postpartum mental disorders. J Clin Psychiatry 2007; 68: 19471953.
  • 126
    Sharma V, Khan M, Corpse C, Sharma P. Missed bipolarity and psychiatric comorbidity in women with postpartum depression. Bipolar Disord 2008; 10: 742747.
  • 127
    Heron J, McGuinness M, Blackmore ER, Craddock N, Jones I. Early postpartum symptoms in puerperal psychosis. BJOG 2008; 115: 348353.
  • 128
    Glover V, Liddle P, Taylor A, Adams D, Sandler M. Mild hypomania (the highs) can be a feature of the first postpartum week. Association with later depression. Br J Psychiatry 1994; 164: 517521.
  • 129
    Lane A, Keville R, Morris M et al. Postnatal depression and elation among mothers and their partners: prevalence and predictors. Br J Psychiatry 1997; 171: 550555.
  • 130
    Farías M, Wenk E, Cordero M. Adaptación de la Escala Highs para la detección de sintomatología hipomaníaca en el puerperio. Trastor Ánimo 2007; 3: 2736.
  • 131
    Heron J, Craddock N, Jones I. Postnatal euphoria: are ‘the highs’ an indicator of bipolarity? Bipolar Disord 2005; 7: 103110.
  • 132
    Sharma V. A cautionary note on the use of antidepressants in postpartum depression. Bipolar Disord 2006; 8: 411414.
  • 133
    Eberhard-Gran M, Eskild A, Opjordsmoen S. Use of psychotropic medications in treating mood disorders during lactation: practical recommendations. CNS Drugs 2006; 20: 187198.
  • 134
    Lutz UC, Wiatr G, Gaertner HJ, Bartels M. Oxcarbazepine treatment during breast-feeding: a case report. J Clin Psychopharmacol 2007; 27: 730732.
  • 135
    Misri S, Corral M, Wardrop AA, Kendrick K. Quetiapine augmentation in lactation: a series of case reports. J Clin Psychopharmacol 2006; 26: 508511.
  • 136
    ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111: 10011020.
  • 137
    McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 107125.
  • 138
    DelBello MP, Hanseman D, Adler CM, Fleck DE, Strakowski SM. Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. Am J Psychiatry 2007; 164: 582590.
  • 139
    Consoli A, Bouzamondo A, Guile JM, Lechat P, Cohen D. Comorbidity with ADHD decreases response to pharmacotherapy in children and adolescents with acute mania: evidence from a metaanalysis. Can J Psychiatry 2007; 52: 323328.
  • 140
    Frazier TW, Demeter CA, Youngstrom EA et al. Evaluation and comparison of psychometric instruments for pediatric bipolar spectrum disorders in four age groups. J Child Adolesc Psychopharmacol 2007; 17: 853866.
  • 141
    Tillman R, Geller B, Klages T et al. Psychotic phenomena in 257 young children and adolescents with bipolar I disorder: delusions and hallucinations (benign and pathological). Bipolar Disord 2008; 10: 4555.
  • 142
    West AE, Henry DB, Pavuluri MN. Maintenance model of integrated psychosocial treatment in pediatric bipolar disorder: a pilot feasibility study. J Am Acad Child Adolesc Psychiatry 2007; 46: 205212.
  • 143
    Fristad MA. Psychoeducational treatment for school-aged children with bipolar disorder. Dev Psychopathol 2006; 18: 12891306.
  • 144
    Tohen M, Kryzhanovskaya L, Carlson G et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007; 164: 15471556.
  • 145
    DelBello MP, Kowatch RA, Adler CM et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45: 305313.
  • 146
    Barzman DH, DelBello MP, Adler CM, Stanford KE, Strakowski SM. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s). J Child Adolesc Psychopharmacol 2006; 16: 665670.
  • 147
    DelBello M, Findling R, Wang P, Gundapaneni B, Versavel M. Safety and efficacy of ziprasidone in pediatric bipolar disorder [Abstract NR4-070]. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 2008.
  • 148
    Biederman J, Mick E, Spencer T, Dougherty M, Aleradi M, Wozniak J. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Bipolar Disord 2007; 9: 888894.
  • 149
    Forbes A, Chang K, Nyilas M et al. Acute efficacy and tolerability of aripiprazole for the treatment bipolar I disorder in pediatric patients [Abstract NR6-048]. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 2008.
  • 150
    Biederman J, Mick E, Spencer T et al. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 2007; 12: 683689.
  • 151
    Tramontina S, Zeni CP, Pheula GF, De Souza CK, Rohde LA. Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial. CNS Spectr 2007; 12: 758762.
  • 152
    Wozniak J, Biederman J, Mick E et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol 2007; 17: 440447.
  • 153
    Findling RL, Short EJ, McNamara NK et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 14451453.
  • 154
    Young RC, Kiosses D, Heo M et al. Age and ratings of manic psychopathology. Bipolar Disord 2007; 9: 301304.
  • 155
    Martino DJ, Igoa A, Marengo E et al. Cognitive and motor features in elderly people with bipolar disorder. J Affect Disord 2008; 105: 291295.
  • 156
    Tsai SY, Lee HC, Chen CC, Huang YL. Cognitive impairment in later life in patients with early-onset bipolar disorder. Bipolar Disord 2007; 9: 868875.
  • 157
    Gildengers AG, Butters MA, Chisholm D et al. Cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. Am J Geriatr Psychiatry 2007; 15: 174179.
  • 158
    Schouws SN, Zoeteman JB, Comijs HC, Stek ML, Beekman AT. Cognitive functioning in elderly patients with early onset bipolar disorder. Int J Geriatr Psychiatry 2007; 22: 856861.
  • 159
    Radanovic M, Nunes PV, Gattaz WF, Forlenza OV. Language impairment in euthymic, elderly patients with bipolar disorder but no dementia. Int Psychogeriatr 2008; 20: 687696.
  • 160
    Depp CA, Cain AE, Palmer BW et al. Assessment of medication management ability in middle-aged and older adults with bipolar disorder. J Clin Psychopharmacol 2008; 28: 225229.
  • 161
    Gildengers AG, Whyte EM, Drayer RA et al. Medical burden in late-life bipolar and major depressive disorders. Am J Geriatr Psychiatry 2008; 16: 194200.
  • 162
    Sajatovic M, Blow FC, Ignacio RV. Psychiatric comorbidity in older adults with bipolar disorder. Int J Geriatr Psychiatry 2006; 21: 582587.
  • 163
    Goldstein BI, Herrmann N, Shulman KI. Comorbidity in bipolar disorder among the elderly: results from an epidemiological community sample. Am J Psychiatry 2006; 163: 319321.
  • 164
    Sajatovic M, Coconcea N, Ignacio RV et al. Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. J Clin Psychiatry 2008; 69: 4146.
  • 165
    Kyomen HH, Whitfield TH, Baldessarini RJ. Levetiracetam for manic behavior in hospitalized geriatric patients with dementia of the Alzheimer’s type. J Clin Psychopharmacol 2007; 27: 408410.
  • 166
    Kyomen HH. The use of levetiracetam to decrease mania in elderly bipolar patients. Am J Geriatr Psychiatry 2006; 14: 985.
  • 167
    Gildengers AG, Butters MA, Chisholm D, Reynolds CF, Mulsant BH. A 12-week open-label pilot study of donepezil for cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. Int J Geriatr Psychiatry 2008; 23: 693698.
  • 168
    Canuto A, Meiler-Mititelu C, Herrmann FR, Delaloye C, Giannakopoulos P, Weber K. Longitudinal assessment of psychotherapeutic day hospital treatment for elderly patients with depression. Int J Geriatr Psychiatry 2008; 23: 949956.
  • 169
    Schaffer A, Mamdani M, Levitt A, Herrmann N. Effect of antidepressant use on admissions to hospital among elderly bipolar patients. Int J Geriatr Psychiatry 2006; 21: 275280.
  • 170
    Lepkifker E, Iancu I, Horesh N, Strous RD, Kotler M. Lithium therapy for unipolar and bipolar depression among the middle-aged and older adult patient subpopulation. Depress Anxiety 2007; 24: 571576.
  • 171
    Depp CA, Lebowitz BD, Patterson TL, Lacro JP, Jeste DV. Medication adherence skills training for middle-aged and elderly adults with bipolar disorder: development and pilot study. Bipolar Disord 2007; 9: 636645.
  • 172
    Merikangas KR, Herrell R, Swendsen J et al. Specificity of bipolar spectrum conditions in the comorbidity of mood and substance use disorders: results from the Zurich cohort study. Arch Gen Psychiatry 2008; 65: 4752.
  • 173
    McDermott BE, Quanbeck CD, Frye MA. Comorbid substance use disorder in women with bipolar disorder associated with criminal arrest. Bipolar Disord 2007; 9: 536540.
  • 174
    Manwani SG, Szilagyi KA, Zablotsky B et al. Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders. J Clin Psychiatry 2007; 68: 11721176.
  • 175
    Berk M, Ng F, Wang WV et al. Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania. J Affect Disord 2008; 110: 126134.
  • 176
    McIntyre RS, Konarski JZ, Soczynska JK et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv 2006; 57: 11401144.
  • 177
    BarChana M, Levav I, Lipshitz I et al. Enhanced cancer risk among patients with bipolar disorder. J Affect Disord 2008; 108: 4348.
  • 178
    Arnold LM, Hudson JI, Keck PE et al. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 2006; 67: 12191225.
  • 179
    Harley C, Li H, Corey-Lisle P, L’Italien GJ, Carson W. Influence of medication choice and comorbid diabetes: the cost of bipolar disorder in a privately insured US population. Soc Psychiatry Psychiatr Epidemiol 2007; 42: 690697.
  • 180
    Dickerson F, Brown CH, Fang L et al. Quality of life in individuals with serious mental illness and type 2 diabetes. Psychosomatics 2008; 49: 109114.
  • 181
    Maina G, Albert U, Rosso G, Bogetto F. Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. J Clin Psychiatry 2008; 69: 609616.
  • 182
    Sheehan DV, McElroy SL, Harnett-Sheehan K et al. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord 2008 Nov 28 [Epub ahead of print].
  • 183
    Benazzi F. Bipolar II disorder: epidemiology, diagnosis and management. CNS Drugs 2007; 21: 727740.
  • 184
    Kupka RW, Altshuler LL, Nolen WA et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 2007; 9: 531535.
  • 185
    Judd LL, Schettler PJ, Solomon DA et al. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord 2008; 108: 4958.
  • 186
    Ruggero CJ, Chelminski I, Young D, Zimmerman M. Psychosocial impairment associated with bipolar II disorder. J Affect Disord 2007; 104: 5360.
  • 187
    Maina G, Albert U, Bellodi L et al. Health-related quality of life in euthymic bipolar disorder patients: differences between bipolar I and II subtypes. J Clin Psychiatry 2007; 68: 207212.
  • 188
    Simonsen C, Sundet K, Vaskinn A et al. Neurocognitive profiles in bipolar I and bipolar II disorder: differences in pattern and magnitude of dysfunction. Bipolar Disord 2008; 10: 245255.
  • 189
    Torrent C, Martinez-Aran A, Daban C et al. Cognitive impairment in bipolar II disorder. Br J Psychiatry 2006; 189: 254259.
  • 190
    Vieta E, Suppes T. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord 2008; 10: 163178.
  • 191
    McMahon FJ, Simpson SG, McInnis MG et al. Linkage of bipolar disorder to chromosome 18q and the validity of bipolar II disorder. Arch Gen Psychiatry 2001; 58: 10251031.
  • 192
    McGrath BM, Wessels PH, Bell EC, Ulrich M, Silverstone PH. Neurobiological findings in bipolar II disorder compared with findings in bipolar I disorder. Can J Psychiatry 2004; 49: 794801.
  • 193
    Arvilommi P, Suominen KS, Mantere OK et al. Adequacy of treatment received by diagnosed and undiagnosed patients with bipolar I and II disorders. J Clin Psychiatry 2007; 68: 102110.
  • 194
    Baldessarini RJ, Leahy L, Arcona S et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 2007; 58: 8591.
  • 195
    Suppes T, Hirschfeld RM, Vieta E, Raines S, Paulsson B. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 2008; 9: 198211.
  • 196
    Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007; 9: 413425.
  • 197
    Hirschfeld RM, Weisler RH, Raines SR, Macfadden W. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67: 355362.
  • 198
    Liebowitz M, Salman E, Mech A et al. Ziprasidone monotherapy in bipolar II depression: an open trial [Abstract NR3-084]. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 2008.
  • 199
    Suppes T, Marangell LB, Bernstein IH et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord 2008; 111: 334343.
  • 200
    Ketter TA, Wang PW, Nowakowska C et al. Divalproex-extended release monotherapy and adjunctive therapy in bipolar II depression. Bipolar Disord 2007; 9 (Suppl. 1): 58.
  • 201
    Parker G, Tully L, Olley A, Hadzi-Pavlovic D. SSRIs as mood stabilizers for bipolar II disorder? A proof of concept study. J Affect Disord 2006; 92: 205214.
  • 202
    Agosti V, Stewart JW. Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression. Int Clin Psychopharmacol 2007; 22: 309311.
  • 203
    Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol 2008; 28: 171181.
  • 204
    Aaronson S, Zuzarte E, Sklar J, Sklar M. Lamotrigine monotherapy with and without bupropion in the treatment of bipolar II depression [Abstract NR3-111]. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 2008.
  • 205
    Altshuler LL, Suppes T, Black DO et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry 2006; 163: 313315.
  • 206
    Bond DJ, Noronha MM, Kauer-Sant’anna M, Lam RW, Yatham LN. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry 2008; 69: 15891601.
  • 207
    Sharma V, Khan M, Corpse C. Role of lamotrigine in the management of treatment-resistant bipolar II depression: a chart review. J Affect Disord 2008; 111: 100105.
  • 208
    Jung I, Lee M, Kang B, Kim M, Lee J. Lamotrigine treatment for patients with bipolar II disorder: retrospective report of 30 cases. Bipolar Disord 2008; 10 (Suppl. 1): 4546.
  • 209
    Kilbourne AM, Post EP, Bauer MS et al. Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. J Affect Disord 2007; 102: 145151.
  • 210
    Suppes T, McElroy SL, Hirschfeld R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists. Psychopharmacol Bull 2007; 40: 2237.
  • 211
    Kim B, Kim SJ, Son JI, Joo YH. Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord 2008; 105: 4552.
  • 212
    Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007; 46: 687700.
  • 213
    Poulin MJ, Chaput JP, Simard V et al. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry 2007; 41: 980989.
  • 214
    Milano W, Grillo F, Del Mastro A et al. Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study. Adv Ther 2007; 24: 123134.
  • 215
    Soreca I, Mauri M, Castrogiovanni S, Simoncini M, Cassano GB. Measured and expected resting energy expenditure in patients with bipolar disorder on maintenance treatment. Bipolar Disord 2007; 9: 784788.
  • 216
    Van Winkel R, De Hert M, Van Eyck D et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008; 10: 342348.
  • 217
    Sicras-Mainar A, Blanca-Tamayo M, Rejas-Gutierrez J, Navarro-Artieda R. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. Eur Psychiatry 2008; 23: 100108.
  • 218
    Jakovljevic M, Crncevic Z, Ljubicic D et al. Mental disorders and metabolic syndrome: a fatamorgana or warning reality? Psychiatr Danub 2007; 19: 7686.
  • 219
    Citrome LL, Holt RI, Zachry WM et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007; 41: 15931603.
  • 220
    Gergerlioglu HS, Savas HA, Celik A et al. Atypical antipsychotic usage-related higher serum leptin levels and disabled lipid profiles in euthymic bipolar patients. Neuropsychobiology 2006; 53: 108112.
  • 221
    Olfson M, Marcus SC, Corey-Lisle P et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006; 163: 18211825.
  • 222
    Gao K, Kemp DE, Ganocy SJ et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008; 28: 203209.
  • 223
    Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128: 3544.
  • 224
    Shen YC, Chen SJ, Lin CC, Chen CH. Concomitant use of lamotrigine and aripiprazole increases risk of Stevens-Johnson syndrome? Int Clin Psychopharmacol 2007; 22: 247248.
  • 225
    Food and Drug Administration. Information for Healthcare Professionals: Carbamazepine. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/carbamazepineHCP.htm. Accessed January 24, 2009.